NICE backs drug for diabetic macular oedema

The National Institute for Health and Clinical Excellence has recommended ranibizumab (Lucentis) for treating visual impairment caused by diabetic macular oedema, after its manufacturer Novartis agreed to provide it at a discounted rate.
Source: Nursing Times Breaking News - Category: Nursing Source Type: news